Predictive Oncology (NASDAQ:POAI) Share Price Crosses Below 200-Day Moving Average – What’s Next?

Predictive Oncology Inc. (NASDAQ:POAI) passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.17 and traded as low as $0.65. Predictive Oncology shares last traded at $0.66, with a volume of 133,587 shares trading hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright assumed coverage on shares of Predictive Oncology in a research report on Monday, August 19th. They set a “buy” rating and a $3.00 target price for the company.

Predictive Oncology Stock Performance

The company has a 50-day moving average of $0.82 and a 200-day moving average of $1.17. The stock has a market capitalization of $4.43 million, a price-to-earnings ratio of -0.20 and a beta of 1.13.

Predictive Oncology (NASDAQ:POAI) last released its quarterly earnings results on Tuesday, August 13th. The medical instruments supplier reported ($0.68) earnings per share for the quarter. The company had revenue of $0.28 million during the quarter. Predictive Oncology had a negative return on equity of 200.06% and a negative net margin of 802.69%. As a group, analysts expect that Predictive Oncology Inc. will post -2.03 earnings per share for the current year.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.